Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients

Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients

The emergence of lamivudine (LAM)-resistant mutants after prolonged LAM therapy may reduce its therapeutic effects against hepatitis B virus (HBV). Adefovir dipivoxil (ADV) is an effective treatment of LAM-resistant HBV infections. However, only limited data are available regarding the safety and ef...

Full description

Bibliographic Details
Main Authors:	Hsin-Wu Lai, Chiu-Chun Chang, Tan-Hsia Chen, Ming-Chang Tsai, Tzy-Yen Chen, Chun-Che Lin
Format:	Article
Language:	English
Published:	Elsevier 2012-08-01
Series:	Journal of the Formosan Medical Association
Subjects:	adefovir dipivoxil hepatitis B surface antigen lamivudine resistance nephrotoxicity renal transplant recipient
Online Access:	http://www.sciencedirect.com/science/article/pii/S0929664612000587

Similar Items

Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
by: Hyun Young Woo, et al.
Published: (2014-06-01)

Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B
by: MA Yanhong
Published: (2013-08-01)

Observation on the effect of adefovir dipivoxil in combined with lamivudine in the treatment of hepatitis B cirrhosis
by: Li Cui
Published: (2017-05-01)

Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B
by: HUANG Meijin
Published: (2014-07-01)

Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection
by: Zhong JH, et al.
Published: (2016-11-01)

Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran
by: Seyed Hamidreza Monavari, et al.
Published: (2013-03-01)

Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients
by: RUAN Bingwei
Published: (2013-02-01)

Adefovir nephrotoxicity in a renal allograft recipient
by: N George, et al.
Published: (2015-01-01)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
by: Jeong Han Kim, et al.
Published: (2014-09-01)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
by: Jeong Han Kim, et al.
Published: (2013-09-01)

Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
by: EunYoung Ze, et al.
Published: (2014-09-01)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
by: Rajeswari Jayakumar, et al.
Published: (2012-01-01)

Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B: preliminary comparative study
by: YAN Haiming
Published: (2013-07-01)

Detection of Mutations Resistant to Lamivudine or Adefovir in HBV and Its Management
by: Jia De-xing, et al.
Published: (2013-12-01)

Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study
by: Shu Yu, et al.
Published: (2014-01-01)

Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis
by: Hu Peng, et al.
Published: (2011-08-01)

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant
by: Ming-Chun Lai, et al.
Published: (2020-01-01)

Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?
by: Qian YY, et al.
Published: (2019-04-01)

HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review
by: Yun Zhang, et al.

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study
by: Zhang Jing, et al.
Published: (2011-09-01)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
by: Hyun Young Woo, et al.
Published: (2020-07-01)

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with non-alcoholic fatty liver disease
by: XIAO Chunhua
Published: (2015-02-01)

Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48 En pacientes con hepatitis crónica B tratados con lamivudina y adefovir el descenso de la viremia en las semanas 12 y 24 tiene valor predictivo de respuesta virológica
by: E. Llop, et al.
Published: (2009-11-01)

Pathological Femoral Fracture due to Osteoporosis and Hypophosphatemic Osteomalacia Following Adefovir Therapy in a Patient with Chronic Hepatitis B
by: Sevilay Batıbay, et al.
Published: (2018-08-01)

Influence of combination mode of PEG-IFNα-2a and adefovir dipivoxil on outcome of patients with HBeAg-positive chronic hepatitis B
by: WU Xioali
Published: (2017-12-01)

Adefovir dipivoxil-induced development of osteomalacia and Fanconi syndrome during the treatment of hepatitis B virus (HBV)-related cirrhosis
by: Orietta Staltari, et al.
Published: (2014-12-01)

Fanconi syndrome with hypophosphatemic osteomalacia induced by low-dose adefovir dipivoxil
by: WANG Shouqing, et al.
Published: (2016-01-01)

Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report
by: Tanaka Motoyuki, et al.
Published: (2012-08-01)

Eficácia do adefovir dipivoxil, entecavir e telbivudina para o tratamento da hepatite crônica B: revisão sistemática The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review
by: Alessandra Maciel Almeida, et al.
Published: (2010-08-01)

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series
by: Nan Chen, et al.
Published: (2018-05-01)

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report
by: Tomohisa Kunii, et al.
Published: (2019-04-01)

Adefovir dipivoxil nella terapia dell’epatite B cronica: profilo farmacologico clinico ed economico
by: Lorenzo Pradelli, et al.
Published: (2005-12-01)

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
by: Byung-Cheol Song
Published: (2016-12-01)

Liquid-Assisted Grinding to Prepare a Cocrystal of Adefovir Dipivoxil Thermodynamically Less Stable than Its Neat Phase
by: Sungyup Jung, et al.
Published: (2015-11-01)

Phase Transformation of Adefovir Dipivoxil/Succinic Acid Cocrystals Regulated by Polymeric Additives
by: Sungyup Jung, et al.
Published: (2013-12-01)

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report
by: Qian Xiang, et al.
Published: (2020-06-01)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
by: Jeong Han Kim, et al.
Published: (2016-06-01)

Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil
by: Zhu S, et al.
Published: (2017-12-01)

LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV
by: Hongyu Jia, et al.
Published: (2015-03-01)

Fanconi syndrome due to prolonged use of low-dose adefovir
by: Xiao-Bing Wang, et al.
Published: (2015-01-01)

Cannot write session to /tmp/vufind_sessions/sess_k6tm58uiv53bilrfb6iia0vu79